ONCOMINE:: A cancer microarray database and integrated data-mining platform

被引:2906
作者
Rhodes, DR
Yu, JJ
Shanker, K
Deshpande, N
Varambally, R
Ghosh, D
Barrette, T
Pandey, A
Chinnaiyan, AM
机构
[1] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Med, Dept Bioinformat, Ann Arbor, MI 48109 USA
[3] Inst Bioinformat, Bangalore, Karnataka, India
[4] Univ Michigan, Sch Med, Dept Biostat, Ann Arbor, MI 48109 USA
[5] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD USA
[6] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD USA
[7] Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA
[8] Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
来源
NEOPLASIA | 2004年 / 6卷 / 01期
关键词
cancer; transcriptome; gene expression; microarray; ONCOMINE;
D O I
10.1016/S1476-5586(04)80047-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
DNA microarray technology has led to an explosion of oncogenomic analyses, generating a wealth of data and uncovering the complex gene expression patterns of cancer. Unfortunately, due to the lack of a unifying bioinformatic resource, the majority of these data sit stagnant and disjointed following publication, massively underutilized by the cancer research community. Here, we present ONCOMINE, a cancer microarray database and web-based data-mining platform aimed at facilitating discovery from genome-wide expression analyses. To date, ONCOMINE contains 65 gene expression datasets comprising nearly 48 million gene expression measurements form over 4700 microarray experiments. Differential expression analyses comparing most major types of cancer with respective normal tissues as well as a variety of cancer subtypes and clinical-based and pathology-based analyses are available for exploration. Data can be queried and visualized for a selected gene across all analyses or for multiple genes in a selected analysis. Furthermore, gene sets can be limited to clinically important annotations including secreted, kinase, membrane, and known gene-drug target pairs to facilitate the discovery of novel biomarkers and therapeutic targets.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 46 条
  • [31] Multiclass cancer diagnosis using tumor gene expression signatures
    Ramaswamy, S
    Tamayo, P
    Rifkin, R
    Mukherjee, S
    Yeang, CH
    Angelo, M
    Ladd, C
    Reich, M
    Latulippe, E
    Mesirov, JP
    Poggio, T
    Gerald, W
    Loda, M
    Lander, ES
    Golub, TR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (26) : 15149 - 15154
  • [32] Rickman DS, 2001, CANCER RES, V61, P6885
  • [33] The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
    Rosenwald, A
    Wright, G
    Chan, WC
    Connors, JM
    Campo, E
    Fisher, RI
    Gascoyne, RD
    Muller-Hermelink, HK
    Smeland, EB
    Staudt, LM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (25) : 1937 - 1947
  • [34] α-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer
    Rubin, MA
    Zhou, M
    Dhanasekaran, SM
    Varambally, S
    Barrette, TR
    Sanda, MG
    Pienta, KJ
    Ghosh, D
    Chinnaiyan, AM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13): : 1662 - 1670
  • [35] Schwartz DR, 2002, CANCER RES, V62, P4722
  • [36] Gene expression correlates of clinical prostate cancer behavior
    Singh, D
    Febbo, PG
    Ross, K
    Jackson, DG
    Manola, J
    Ladd, C
    Tamayo, P
    Renshaw, AA
    D'Amico, AV
    Richie, JP
    Lander, ES
    Loda, M
    Kantoff, PW
    Golub, TR
    Sellers, WR
    [J]. CANCER CELL, 2002, 1 (02) : 203 - 209
  • [37] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
    Slamon, DJ
    Leyland-Jones, B
    Shak, S
    Fuchs, H
    Paton, V
    Bajamonde, A
    Fleming, T
    Eiermann, W
    Wolter, J
    Pegram, M
    Baselga, J
    Norton, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) : 783 - 792
  • [38] Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
    Sorlie, T
    Perou, CM
    Tibshirani, R
    Aas, T
    Geisler, S
    Johnsen, H
    Hastie, T
    Eisen, MB
    van de Rijn, M
    Jeffrey, SS
    Thorsen, T
    Quist, H
    Matese, JC
    Brown, PO
    Botstein, D
    Lonning, PE
    Borresen-Dale, AL
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (19) : 10869 - 10874
  • [39] A direct approach to false discovery rates
    Storey, JD
    [J]. JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 2002, 64 : 479 - 498
  • [40] Tanwar MK, 2002, CANCER RES, V62, P4364